Novel strategy for lung cancer risk stratification through the assessment of epigenetic alteration in oral eputhelium

2016 Fiscal Year Final Research Report

• Project/Area Number: 26462143
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory surgery
• Research Institution: Department of Clinical Research, National Hospital Organization Kure Medical Center
• Principal Investigator: Harada Hiroaki 独立行政法人国立病院機構(呉医療センター臨床研究部), その他部局等, その他(移行) (90573816)
• Co-Investigator(Renkei-kenkyūsha): OKADA Morihito 広島大学, 原爆放射線医科学研究所, 教授 (70446045)
• Research Collaborator: KIMURA Masami
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: 肺癌 / 手術 / 分子生物学的マーカー / エピジェネティクス / メチル化 / 早期発見 / 予後因子

Outline of Final Research Achievements

In the assessment of the role of epigenetic alteration as a prognostic biomarker for lung cancer, using resected lung tumor tissues, we demonstrated that methylated DLX4, PCDH10, and MDFI can be potential biomarkers that predict prognosis after curative resection of pathologically node-negative non-small cell lung cancer.
In the assessment of the role of epigenetic alteration as a biomarker for early detection of lung cancer, we found a significant difference in the methylation profiles of oral epithelium between lung cancer patients and controls. When the methylation profiles of GDNF, RARB, HS3ST2 and HOXD11 were combined, high specificity and a positive predictive value for the risk assessment of lung cancer were demonstrated.These results indicated that the assessment of epigenetic alterations using oral epithelium may help to identify a high risk of lung cancer in individuals.

Free Research Field

呼吸器外科